02992nas a2200313   4500008004100000020001400041024001700055245015000072210006900222260031200291300001400603490000700617520172600624653002802350653002602378653001602404653001602420653002002436100001902456700001702475700001902492700002002511700002602531700002202557700002002579700001602599700001802615856004502633       2013                        eng d  a0041-1337  awej, 013214400aPrevention of De Novo Hepatitis B in Recipients of Core Antibody-Positive Livers With Lamivudine and Other Nucleos(t)ides:  A 12-Year Experience.0 aPrevention of De Novo Hepatitis B in Recipients of Core Antibody  a(C) 2013 Lippincott Williams & Wilkins, Inc.b(1) Division of Gastroenterology, Hepatology and Endoscopy, Brigham and Women's Hospital, Boston, MA.(2) Division of Gastroenterology and Hepatology, Department of Medicine, Weill Cornell Medical College, New York, NY.(3) Center for Liver Disease and Tranc2013  a960 - 9650 v953 aBackground: Lamivudine (LAM) has been shown to prevent de novo hepatitis B virus (HBV) infection in recipients of hepatitis B core antibody (HBcAb)-positive liver transplants (LT) but primarily in small studies with limited follow-up., Methods: We conducted a retrospective cohort study of HBcAb+ graft recipients at our institution from October 1999 to August 2008., Results: One hundred nineteen recipients without prior HBV were identified (median age, 54 years; 70% male), of which 62 received LAM. The median follow-up was 2.6 years overall and 5.3 years in the LAM group. Among LAM recipients, 44% were HBV naive (HBsAb-/HBcAb-) at LT, of which 6% developed HBsAb+ and 3% developed HBcAb+ after LT. Eight percent developed de novo HBV: two recipients became hepatitis B surface antigen positive at 70 and 23 months and three experienced breakthrough with HBV DNA more than 2000 IU at 1 to 9 months after LT. Sixty percent (3 of 5) were HBV naive. Four (6%) other recipients also had transiently detectable HBV less than 2000 IU, which did not require any changes to their prophylaxis regimen. When compared with recipients who received other nucleos(t)ide analogues, there was no difference in de novo rates: LAM 8% (5 of 62), adefovir 15% (5 of 33), tenofovir 0% (0 of 3), entecavir 0% (0 of 1), and 5% (1 of 20) for those not given prophylaxis (P=0.59)., Conclusions: LAM monoprophylaxis was effective in preventing de novo HBV in the vast majority of recipients over long-term follow-up. Adefovir had a higher rate of de novo infections numerically, whereas tenofovir and entecavir had no cases and may be more effective, but this was limited by a small sample size., (C) 2013 Lippincott Williams & Wilkins, Inc.10aExtended criteria donor10aLiver Transplantation10aNucleotides10aprophylaxis10aViral hepatitis1 aChang, Matthew1 aOlsen, Sonja1 aPichardo, Elsa1 aStiles, Jessica1 aRosenthal-Cogan, Lori1 aBrubaker, William1 aGuarrera, James1 aEmond, Jean1 aBrown, Robert  uhttps://notifylibrary.org/reference/4052